CDEK
← All drugs Report issue

monalizumab

mAbexperimental

Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers. — Wikipedia

Clinical trial activity

24 trials · 28 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
21
Phase 3
2
Phase 4
0

Earliest trial started May 1, 2011 (NCT01370902)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • iph2201
  • monalizumab
  • monalizumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06769126Phase 2Dec 1, 2025National Cancer Institute (NCI), SWOG Cancer Research Network
NCT07146230Phase 2Sep 30, 2025AstraZeneca, Yeshiva University
NCT06503614Phase 2Dec 31, 2024AstraZeneca, Hoosier Cancer Research Network, Icahn School of Medicine at Mount Sinai
NCT06152523Phase 2Dec 31, 2023Assistance Publique - Hôpitaux de Paris
NCT05903092Phase 2Sep 26, 2023AstraZeneca, Hoosier Cancer Research Network, Wayne State University
NCT05414032Phase 2Jul 31, 2022AstraZeneca, Eli Lilly, University of Toronto
NCT05221840Phase 3Feb 7, 2022AstraZeneca, Institut Gustave Roussy
NCT05061550Phase 2Dec 20, 2021AstraZeneca, Parexel, University of Texas at Houston
NCT06892223Phase 2Dec 3, 2021Istituto Clinico Humanitas - Rozzano (MI), Italy
NCT04590963Phase 3Oct 2, 2020AstraZeneca, Centre Leon Berard, Innate Pharma, University of Pennsylvania
NCT04307329Phase 2May 1, 2020AstraZeneca, Netherlands Cancer Institute, University of Amsterdam
NCT04333914Phase 2Apr 15, 2020Centre Leon Berard
NCT04145193Phase 2Jan 30, 2020MedImmune
NCT03833440Phase 2Mar 31, 2019Aix-University of Marseille
NCT03794544Phase 2Mar 8, 2019MedImmune
NCT03822351Phase 2Dec 19, 2018MedImmune
NCT03307941Phase 1/Phase 2 (Phase 2)Jul 20, 2017Free University of Brussels, Innate Pharma
NCT03088059Phase 2Jul 1, 2017European Organisation for Research and Treatment of Cancer
NCT02921685Phase 1Oct 1, 2016Innate Pharma, Institut Paoli-Calmettes
NCT02643550Phase 1/Phase 2 (Phase 2)Dec 1, 2015Innate Pharma
Showing 20 of 24 trials
Page 1 / 2

Organizations

Research & Development (28)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstraZenecaFor profit8322020
Innate PharmaFor profit8432011
MedImmuneFor profit3312018
Centre Leon BerardAcademic/Hospital2122020
Hoosier Cancer Research NetworkAcademic/Hospital2212023
Aix-University of MarseilleAcademic/Hospital1112019
Assistance Publique - Hôpitaux de ParisAcademic/Hospital1112023
British Columbia Cancer AgencyAcademic/Hospital1012015
Canadian Cancer Trials GroupAcademic/Hospital1112015
Eli LillyFor profit1012022
European Organisation for Research and Treatment of CancerAcademic/Hospital1112017
Free University of BrusselsAcademic/Hospital1112017
Icahn School of Medicine at Mount SinaiAcademic/Hospital1012024
Institut Gustave RoussyAcademic/Hospital1012022
Institut Paoli-CalmettesAcademic/Hospital1112016
Istituto Clinico Humanitas - Rozzano (MI), ItalyAcademic/Hospital1112021
McMaster UniversityAcademic/Hospital1012015
National Cancer Institute (NCI)Government1012025
Netherlands Cancer InstituteAcademic/Hospital1112020
Ohio State UniversityAcademic/Hospital1012015
28 organizations
Page 1 / 2